Efficacy analysis on autologous blood circulation pipe in preventing first use syndrome of hemodialysis patients

Objective To study the feasibility of using autologous blood circulation pipe syndrome in preventing the first use syndrome (FUS) of hemodialysis patients,improve the quality of dialysis,reduce patients' sufering and medical expenses.Methods The sample pool of 156 maintenance hemodialysis patients with 1158 times of hemodialysis,were divided into control and experimental groups.Normal hemodialysis practices were applied to control group,while 10-15 min of autologous blood circulation pipe after the preshoot of dialyser and pipes practices were applied to experimental group.A comparison of possibility of FUS and in vitro coagulation was conducted between the two groups.Results In the control group with patients given dialysis treatment in 560 cases,there were 23 cases of FUS,the rate was 4.11％,while the experimental group treated dialysis patients in 598 cases,there were 5 cases of FUS,the rate was 0.84％.FUS incidence in the experimental group was significantly lower than that of the control group,the difference was statistically significant (P ＜ 0.01),whereas the incidence of the in vitro coagulation showed no significant change,the difference was not statistically significant (P ＞ 0.05).Conclusion The application of autologous blood circulation pipe is effective in preventing FUS during hemodialysis treatment,meanwhile no bleeding or in vitro coagulation risk increases. Key words: Autologous blood circulation pipe;  Prevention;  Hemodialysis;  First-use syndrome (FUS); Efficacy analysis